Capricorn Fund Managers’s MoonLake Immunotherapeutics MLTX Stock Holding History

Capricorn Fund Managers’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.29M	Buy	+374,866	New	+$6.8M	0.58%	50

Other funds holding MLTX

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

SJS Investment Consulting Sylvania, Ohio $919M AUM 23.4% 1-Year Est. Return

Capricorn Fund Managers's MLTX Position: Q2 2026 in Review

Capricorn Fund Managers opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 374,866 shares worth $7.29M. The stake represents 0.58% of the portfolio and ranks #50 among its holdings.

14 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Capricorn Fund Managers held 374,866 shares of MoonLake Immunotherapeutics worth $7.29M as of Q2 2026.
MoonLake Immunotherapeutics was a new Capricorn Fund Managers position in Q2 2026.
MoonLake Immunotherapeutics made up 0.58% of Capricorn Fund Managers's portfolio in Q2 2026, its #50 holding.
14 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Capricorn Fund Managers's 13F filing for Q2 2026, filed 24 Jul 2026.